Observation on the efficacy and changes in iron metabolism of standard initial dose Roxadustat in the treatment of non-dialysis renal anemia patients with different CKD stages

LU Xiao-fan; ZHANG Yan-ning

doi:10.19538/j.nk2024020111

Abstract：Objective To observe the efficacy and changes of iron metabolism of standard dose Roxadustat in the treatment of non-dialysis renal anemia patients with different chronic kidney disease(CKD)stages.Methods The data of 36 non-dialysis CKD3-5 patients with renal anemia and substandard hemoglobin(Hb)were retrospectively analyzed from June 2021 to October 2022 in the Department of Nephrography of the Northern Theater Command Hospital.CKD stage3 and 4 were treated as group A(20 cases),and CKD stage 5 was treated as group B(16 cases).All patients were treated with Roxadustat at the standard starting dose.The changes of anemia,biochemical and iron metabolism indexes and adverse reactions were compared before and 3 months after Roxadustat treatment.Results Before treatment,Hb,red blood cell count,hematocrit and transferrin saturation in group A were higher than those in group B,with statistical significance(P＜0.05).There was no significant difference in ferritin,serum iron and hypersensitive C-reactive protein between the two groups(P＞0.05).After treatment,the Hb compliance rate of group A and group B patients was 80.0％and 62.5％,respectively,with no statistical significance(P=0.285).There were no significant differences in Hb,hematocrit,erythrocyte count,ferritin,transferrin saturation,serum iron and hypersensitive C-reactive protein between 2 groups(P＞0.05).After treatment,Hb,hematocrit and red blood cell count were increased compared with those before treatment,and the differences were statistically significant(P＜0.05).During the treatment period,2 patients had hyperkalemia and 5 patients had mild gastrointestinal symptoms,all of which were tolerable.No adverse cardiovascular events occurred in all patients.Conclusion The standard dose of Roxadustat has good clinical efficacy and high safety in the treatment of non dialysis renal anemia patients with different CKD stages.